Bridgewater, MA -- (SBWIRE) -- 03/20/2013 -- The StockConsultant stock screener has found Array Biopharma Inc (NASDAQ:ARRY) as an uptrend stock at support with very good upside trade quality.
Array Biopharma Inc (NASDAQ:ARRY) founded in 1998 and headquartered in Boulder, CO is a biotech company which focuses on the discovery and development of targeted small molecule drugs to treat cancer and inflammatory diseases. ARRY stock price is up 0.7% today and is in a mild uptrend with a recent pullback to support. The stock has very good upside trade quality and a price target T1 of 4.63.
ARRY upside trade details:
TRADE QUALITY - 85%, V. Good
TARGET 1 - Price: 4.63 Profit: 12.7%, for a typical rally.
Stop Limit/Trailing Stop Limit: 3.97 Loss: 3.4%
Profit/Loss Ratio: 3.7 : 1 - Good
Full ARRY Stock Consultant report with charts and analysis
StockConsultant.com provides automated stock consulting and advanced screener on over 6000 US equities. Each detailed stock report contains easy to use technical analysis indicators, charts, and news to fine tune stock entry and exit price levels.
Disclosure: StockConsultant.com and its employees are not registered investment advisors and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Please check with a registered investment advisor before making any investment decisions.
For our full disclaimer please visit: http://www.stockconsultant.com/disclaimerpage.html
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)